Artichoke

Artichoke (Cynara scolymus, also written Cynara cardunculus var. scolymus) is a tall Mediterranean perennial of the Asteraceae family, cultivated for the unopened violet flower heads eaten as a vegetable and, in herbal medicine, for the large basal leaves harvested before flowering. The signature bioactive groups in the leaf are cynarin (a hydroxycinnamic acid derivative), chlorogenic acid, and bitter-tasting sesquiterpene lactones. The traditional indication is dyspeptic complaints; modern phytotherapy uses standardised leaf extracts in the same area.

The European Medicines Agency Committee on Herbal Medicinal Products (EMA HMPCEuropean Medicines Agency, Committee on Herbal Medicinal Products (HMPC)) registers artichoke leaf in traditional use for relief of symptoms of dyspepsia such as bloating, fullness, flatulence, and post-meal discomfort. The HMPC assessment report concluded that well-established use could not be established because the clinical data were insufficient. The current EMA monograph carries this single digestive indication; the supportive use in mild hyperlipidaemia is framed by ESCOP and small trials rather than by a named EMA indication. The German Commission E published a positive monograph for dyspeptic complaints. Named clinical work includes Holtmann and colleagues in 2003 (functional dyspepsia and irritable bowel symptoms, leaf extract, randomised trial), Bundy and colleagues in 2008 (randomised cholesterol trial in adults with mild hypercholesterolaemia, modest signal), and a 2013 Cochrane review by Wider and colleagues that pooled cholesterol trials and described mixed evidence. Reading: the dyspepsia indication carries the stronger evidence; the cholesterol indication remains traditional-supportive in framing.

Artichoke has been cultivated around the Mediterranean since antiquity. Greek and Roman writers describe it as both a food and a remedy for the digestion and the liver, and the unopened flower head has stayed a fixture of Italian and southern French kitchens through every subsequent century. The leaves and the roots, not the edible head, are the parts that European herbalists used as a bitter digestive tonic and as a liver and gallbladder herb.

In Austria, artichoke is primarily an imported culinary vegetable, much more familiar from the supermarket and the Italian deli than from the home garden. Its herbal-medicine presence runs along a parallel track: standardised leaf extracts such as Hepar SL and Cynarix are established pharmacy preparations sold for dyspeptic complaints under the EMA HMPCEuropean Medicines Agency, Committee on Herbal Medicinal Products (HMPC) traditional-use framing, and you will find them in any Austrian Apotheke. The herb is therefore best read as a Mediterranean import that arrived in two streams, one culinary and one as a commercial phytotherapeutic.

Two mechanism stories sit alongside the artichoke evidence base. The first, dyspepsia, is the better-grounded one: cynarin is choleretic (it increases bile flow), and the bitter sesquiterpene lactones in the leaf act on bitter taste receptors and on upper-digestive secretion. This is the mechanism most often cited for the EMA HMPCEuropean Medicines Agency, Committee on Herbal Medicinal Products (HMPC) traditional-use dyspepsia indication, and it matches the traditional bitter-tonic role of the herb.

The second story, lipid metabolism, is more tentative. In laboratory and animal work, cynarin and chlorogenic acid have been examined for effects on cholesterol pathways, including HMG-CoA reductase modulation and bile acid metabolism. The clinical translation, as the Wider 2013 Cochrane review summarised, remains uneven and the effect sizes in human trials are small. The traditional and modern evidence support a supportive role in dyspeptic complaints under the EMA HMPCEuropean Medicines Agency, Committee on Herbal Medicinal Products (HMPC) traditional-use framing, and an ESCOP and small-trial supportive role in mild hyperlipidaemia, not a "lowers cholesterol" or "heals the liver" mechanism in any specific therapeutic sense.

Modern research on artichoke leaf has focused on cynarin and chlorogenic acid, and on the bitter sesquiterpene lactones, as the chemical signatures of the extract. Holtmann and colleagues in 2003 reported a randomised trial of standardised artichoke leaf extract in functional dyspepsia and irritable bowel symptoms and found a modest improvement in symptom scores against placebo. Bundy and colleagues in 2008 ran a randomised trial in adults with mild hypercholesterolaemia and reported a small reduction in total cholesterol; a 2013 Cochrane systematic review by Wider and colleagues pooled the available cholesterol trials and described the evidence base as small and heterogeneous, with mixed results.

The honest reading: the dyspepsia indication is the better-supported one and carries the EMA HMPCEuropean Medicines Agency, Committee on Herbal Medicinal Products (HMPC) traditional-use registration; the assessment report concluded that well-established use could not be established because the clinical data were insufficient. The hyperlipidaemia indication sits in ESCOP plus small-trial territory and is not a named indication in the current EMA monograph, which carries the single digestive indication; it is best read as supportive treatment of mild hyperlipidaemia rather than as proven effect on a cardiovascular endpoint. There is no permitted EFSA health claim for artichoke. The clinical signals reported in named trials are framed at the symptom level, not at hard clinical endpoints.

Forms and preparation

The culinary artichoke is the closed, unopened flower head, boiled or steamed whole and eaten leaf by leaf with vinaigrette or melted butter; this is the form most familiar in Italian and southern French cooking, and it is not the medicinal form. The medicinal part is the large basal leaf, harvested before the plant flowers and dried for use. For a leaf tea, use one to two grams of dried leaf per cup, pour freshly boiled water, cover, and let steep for ten minutes before straining. Sweeten with honey if you like; the tea is strongly bitter, and that bitterness is part of the digestive effect. Standardised leaf-extract preparations are the form most commonly used in modern Austrian phytotherapy and in the named clinical trials. Examples sold in Austrian pharmacies include Hepar SL and Cynarix. Tinctures and powdered leaf are also available. Capsules and tablets give a predictable cynarin dose; the tea gives the traditional bitter experience that triggers the digestive response. Take any artichoke leaf preparation shortly before a meal.

Dosage

For the leaf tea, the traditional range is three cups per day, taken shortly before meals; one to two grams of dried leaf per cup. For standardised leaf-extract products, the dose used in the named clinical trials and the EMA HMPC monograph ranges from around 320 to 1600 milligrams of extract per day, divided across meals, with the actual cynarin content varying by product. Read the label to know what your specific extract delivers. Build slowly. Start at the lower end of the range for the first week and see how your digestion responds before adjusting. Artichoke leaf is traditionally taken in courses of several weeks for digestive complaints rather than continuously without review. If you have gallstones, biliary obstruction, or any prescription medicine that affects bile flow, see the warnings below and talk to a doctor or pharmacist before starting.